These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 28844952)
21. Molecular Profiling and Targeted Therapy in Cholangiocarcinoma: An Observational, Retrospective Multicenter Study. Garcia-Pardo M; Ortega L; Fernández-Aceñero MJ; García Alfonso P; Martín M; Muñoz AJ J Gastrointest Cancer; 2021 Jun; 52(2):814-818. PubMed ID: 33683644 [TBL] [Abstract][Full Text] [Related]
23. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA. Wang C; Chen C; Hu W; Tao L; Chen J Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206 [TBL] [Abstract][Full Text] [Related]
24. Current challenges to underpinning the genetic basis for cholangiocarcinoma. Cigliano A; Chen X; Calvisi DF Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):511-526. PubMed ID: 33888034 [TBL] [Abstract][Full Text] [Related]
25. Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma. Tomlinson JL; Li B; Yang J; Loeuillard E; Stumpf HE; Kuipers H; Watkins R; Carlson DM; Willhite J; O'Brien DR; Graham RP; Chen X; Smoot RL; Dong H; Gores GJ; Ilyas SI J Hepatol; 2024 Jun; 80(6):892-903. PubMed ID: 38458319 [TBL] [Abstract][Full Text] [Related]
26. Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study. Zhang C; You X; Zhang Q; Wang D Invest New Drugs; 2024 Feb; 42(1):24-34. PubMed ID: 37975978 [TBL] [Abstract][Full Text] [Related]
27. The state of therapy modalities in clinic for biliary tract cancer. Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261 [TBL] [Abstract][Full Text] [Related]
28. FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma. Mahipal A; Tella SH; Kommalapati A; Anaya D; Kim R Cancer Treat Rev; 2019 Aug; 78():1-7. PubMed ID: 31255945 [TBL] [Abstract][Full Text] [Related]
30. Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review). Yang S; Zou R; Dai Y; Hu Y; Li F; Hu H Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37888583 [TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma. Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978 [TBL] [Abstract][Full Text] [Related]
33. The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. Chong DQ; Zhu AX Oncotarget; 2016 Jul; 7(29):46750-46767. PubMed ID: 27102149 [TBL] [Abstract][Full Text] [Related]
34. Role of inflammation and proinflammatory cytokines in cholangiocyte pathophysiology. Pinto C; Giordano DM; Maroni L; Marzioni M Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1270-1278. PubMed ID: 28754451 [TBL] [Abstract][Full Text] [Related]
35. Pathological features of primary sclerosing cholangitis identified by bile proteomic analysis. Rupp C; Bode KA; Leopold Y; Sauer P; Gotthardt DN Biochim Biophys Acta Mol Basis Dis; 2018 Apr; 1864(4 Pt B):1380-1389. PubMed ID: 28943450 [TBL] [Abstract][Full Text] [Related]
36. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma. Nevi L; Di Matteo S; Carpino G; Zizzari IG; Samira S; Ambrosino V; Costantini D; Overi D; Giancotti A; Monti M; Bosco D; De Peppo V; Oddi A; De Rose AM; Melandro F; Bragazzi MC; Faccioli J; Massironi S; Grazi GL; Panici PB; Berloco PB; Giuliante F; Cardinale V; Invernizzi P; Caretti G; Gaudio E; Alvaro D Hepatology; 2021 Jan; 73(1):144-159. PubMed ID: 32978808 [TBL] [Abstract][Full Text] [Related]